SG11202003956TA - A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient - Google Patents

A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient

Info

Publication number
SG11202003956TA
SG11202003956TA SG11202003956TA SG11202003956TA SG11202003956TA SG 11202003956T A SG11202003956T A SG 11202003956TA SG 11202003956T A SG11202003956T A SG 11202003956TA SG 11202003956T A SG11202003956T A SG 11202003956TA SG 11202003956T A SG11202003956T A SG 11202003956TA
Authority
SG
Singapore
Prior art keywords
patient
treating
compounds
treatment groups
classifying
Prior art date
Application number
SG11202003956TA
Other languages
English (en)
Inventor
Suk Peng Chew
Salvatore Albani
Kah-Hoe Pierce Chow
Lu Pan
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Publication of SG11202003956TA publication Critical patent/SG11202003956TA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
SG11202003956TA 2017-11-30 2018-11-29 A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient SG11202003956TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201709924T 2017-11-30
PCT/SG2018/050585 WO2019108135A1 (en) 2017-11-30 2018-11-29 A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient

Publications (1)

Publication Number Publication Date
SG11202003956TA true SG11202003956TA (en) 2020-06-29

Family

ID=66665136

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003956TA SG11202003956TA (en) 2017-11-30 2018-11-29 A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient

Country Status (7)

Country Link
US (1) US20210341483A1 (zh)
EP (1) EP3717915B1 (zh)
JP (1) JP7355294B2 (zh)
CN (1) CN111670364B (zh)
ES (1) ES2982438T3 (zh)
SG (1) SG11202003956TA (zh)
WO (1) WO2019108135A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111883203B (zh) * 2020-07-03 2023-12-29 上海厦维医学检验实验室有限公司 用于预测pd-1疗效的模型的构建方法
WO2023091954A2 (en) * 2021-11-19 2023-05-25 The Trustees Of The University Of Pennsylvania Engineered pan-leukocyte antigen cd45 to facilitate car t cell therapy
CN116087499B (zh) * 2023-02-20 2023-10-31 深圳裕康医学检验实验室 一种癌样本的染色方法及试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003903387A0 (en) * 2003-07-02 2003-07-17 Sirtex Medical Limited Combination therapy for treatment of neoplasia
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US9726676B2 (en) * 2010-09-24 2017-08-08 Niels Grabe Means and methods for the prediction of treatment response of a cancer patient
AP2013007158A0 (en) * 2011-03-11 2013-10-31 Gilead Calistoga Llc Combination therapies for hematologic malignancies
NZ712314A (en) * 2013-03-15 2021-07-30 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
US20160312295A1 (en) * 2013-12-17 2016-10-27 Merck Sharp & Dohme Corp. Gene signature biomarkers of tumor response to pd-1 antagonists
US10550186B2 (en) * 2014-12-04 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting intercellular adhesion molecule 4 (ICAM4)
EP3283083A4 (en) * 2015-04-15 2018-10-31 Prospect Chartercare RWMC LLC D/B/A Roger Williams Medical Center Hepatic arterial infusion of car-t cells

Also Published As

Publication number Publication date
EP3717915B1 (en) 2024-04-10
WO2019108135A1 (en) 2019-06-06
EP3717915A4 (en) 2021-10-27
CN111670364A (zh) 2020-09-15
EP3717915C0 (en) 2024-04-10
CN111670364B (zh) 2024-02-02
ES2982438T3 (es) 2024-10-16
WO2019108135A9 (en) 2019-07-04
EP3717915A1 (en) 2020-10-07
JP7355294B2 (ja) 2023-10-03
US20210341483A1 (en) 2021-11-04
JP2021504682A (ja) 2021-02-15

Similar Documents

Publication Publication Date Title
IL277159A (en) Therapeutic cell systems and methods for treating cancer and infectious diseases
ZA201901504B (en) System and method for controlled medical therapy
EP3766431A4 (en) MEDICAL DEVICE AND TREATMENT METHOD
EP3622407A4 (en) PATIENT TREATMENT SYSTEMS AND METHODS
EP3325622C0 (en) SYSTEM, DEVICE AND METHOD FOR DELIVERING THERAPY OR TREATMENT FOR CANCER AND OTHER DISEASES
HK1257321A1 (zh) 用於治療腦組織的組織摧毀術治療系統和方法
IL282871A (en) Systems and methods for skin care
IL256256A (en) System and method for extracorporeal blood treatment
GB2583322B (en) Method for managing behavioral treatment therapy and devices thereof
IL269083A (en) Methods for the prevention and treatment of heart diseases
GB2525023B (en) Apparatus and method for treating a patient having a heart
SG11202003956TA (en) A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient
IL281439A (en) Combined treatment for blood cancer
PL3731893T3 (pl) Urządzenie do pozaustrojowego oczyszczania krwi
EP3508148A4 (en) MEDICAL DEVICE AND TREATMENT METHOD
EP3505110A4 (en) MEDICAL DEVICE AND TREATMENT METHOD
EP3318292A4 (en) Single x-ray source blood irradiation device and irradiation method thereof
EP3508149A4 (en) MEDICAL DEVICE AND TREATMENT METHOD
EP3427678A4 (en) MEDICAL DEVICE AND TREATMENT METHOD
IL284462A (en) Tissue treatment systems and methods
GB2575031B (en) Skin treatment apparatus
IL286680A (en) A drug to treat cancer
EP4082577A4 (en) CANCER TREATMENT METHOD AND DRUG
GB201500512D0 (en) Therapeutic treatment methods, and apparatus for use therein
CA195803S (en) Skin treatment apparatus